<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Acquir Immune Defic Syndr</journal-id><journal-id journal-id-type="iso-abbrev">J. Acquir. Immune Defic. Syndr</journal-id><journal-id journal-id-type="publisher-id">qai</journal-id><journal-title-group><journal-title>Journal of Acquired Immune Deficiency Syndromes (1999)</journal-title></journal-title-group><issn pub-type="ppub">1525-4135</issn><issn pub-type="epub">1944-7884</issn><publisher><publisher-name>JAIDS Journal of Acquired Immune Deficiency Syndromes</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4819527</article-id><article-id pub-id-type="publisher-id">QAIV16389</article-id><article-id pub-id-type="doi">10.1097/QAI.0000000000000916</article-id><article-id pub-id-type="art-access-id">00021</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial: Erratum</article-title></title-group><pub-date pub-type="ppub"><day>1</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>11</day><month>12</month><year>2015</year></pub-date><volume>71</volume><issue>1</issue><fpage>e33</fpage><lpage>e33</lpage><permissions><copyright-statement>Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement><copyright-year>2015</copyright-year></permissions><self-uri xlink:type="simple" xlink:href="qai-71-e33.pdf"></self-uri><custom-meta-group><custom-meta><meta-name>STATUS</meta-name><meta-value>ONLINE-ONLY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><offsets xml_i="2010" xml_f="2061" txt_i="7" txt_f="58">In the article by Walmsley et al, appearing in the </offsets><italic><offsets xml_i="2069" xml_f="2116" txt_i="58" txt_f="105">Journal of Acquired Immune Deficiency Syndromes</offsets></italic><offsets xml_i="2125" xml_f="2804" txt_i="105" txt_f="784">, Vol. 70, No. 5, pp. 515–519, entitled “Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial,” there is an error in the abstract text regarding the incidence of discontinuations due to adverse events through week 144. The sentence should read, “Superior efficacy was primarily driven by fewer discontinuations due to adverse events in the dolutegravir + abacavir/lamivudine arm [dolutegravir + abacavir/lamivudine arm, 16 (4%); efavirenz/tenofovir/emtricitabine arm, 58 (14%)] through W144.” The data in the body of the manuscript are correct.</offsets></p></body><back><ref-list><title>REFERENCE</title><ref id="R1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walmsley</surname><given-names>S</given-names></name><name><surname>Baumgarten</surname><given-names>A</given-names></name><name><surname>Berenguer</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naïve patients: week 96 and week 144 results from the SINGLE randomized clinical trial</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2015</year>;<volume>70</volume>:<fpage>515</fpage>–<lpage>519</lpage>.<pub-id pub-id-type="pmid">26262777</pub-id></mixed-citation></ref></ref-list></back></article>